Erin Crum, MPH, director of quality reporting, McKesson, discusses being granted approval again to participate in MIPS, what is new for 2018, and how the company is situated to support the three MIPS practice-reported categories.
Robin T Zon, MD, FACP, FASCO, and Bobby Daly, MD, MBA, discuss ASCO's recently published results of an evaluation of national pathway vendors against the Criteria for High-Quality Clinical Pathways.
Bobby Daly, MD, MBA, and Ray D Page, DO, PhD, discuss the ramifications of clinical pathway vendor conflicts of interest and the potential issues of full transparency on the part of committee members.
To better understand how clinical pathways are developed and executed in cardiovascular care, Journal of Clinical Pathways spoke with researchers from University of Chicago Medicine (Chicago, IL), who developed a multifaceted Acutely Decompensated Heart Failure Clinical Pathway program to reduce inpatient readmission rates.
To gain more insight into this partnership and the future of tumor profiling in cancer treatment, Journal of Clinical Pathways spoke with Nicholas J Petrelli, MD, FACS, Bank of America-endowed medical director of Christiana Care’s Helen F. Graham Cancer Center & Research Institute.
John Danaher, MD, President of Clinical Solutions, Elsevier, and Kathy Lokay, President and CEO, Via Oncology, speak on behalf of their respective companies regarding Elsevier's recent acquisition of Via Oncology.
Tanner Caverly, MD, MPH, explains the impact of high false-positive rates following initial low-dose CT screening for lung cancer and the associated cost implications.
To gain a better understanding of the newly available options for patients with this hematologic malignancy, Journal of Clinical Pathways spoke with Natalie S Callander, MD, professor of hematology/oncology at University of Wisconsin School of Medicine and Public Health (Madison, WI).
Journal of Clinical Pathways recently spoke with Dr Page about the continued validation of the VeriStrat test, the role of testing within clinical pathways, and their effect on the OCM.
Journal of Clinical Pathways spoke with Editorial Advisory Board member Ayman Elfiky, MD, MSc, MPH, about how clinical pathways are used at Dana-Farber Cancer Institute (Boston, MA).